Let's raise $75,000 in 75 hours to celebrate BDC and NBDF's 75th anniversary!If you are at BDC, a minimum donation of $5 or more will earn you a custom made #BDC2023 friendship bracelet! Bring your donation receipt to the NBDF booth in the…
Washington, D.C. - The APLUS Coalition, an alliance of patient advocacy organizations, has announced a new joint statement in a show of solidarity for those living with conditions requiring the use of blood and/or plasma products. The statement…
Equitable Access to Behavioral Health Treatment for the Bleeding Disorders Community
Speaker(s): Kate Reinhalter Bazinsky (she/her): Chair, Bleeding Disorders Substance Use & Mental Health Access Coalition…
National Research Blueprint: An Introduction
Speaker(s): NHF Research Team
NHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn about the…
National Research Blueprint: A Continued Conversation
Speaker(s): NHF Research Team
NHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn…
April is National Minority Health Month. To learn about the experiences of the bleeding disorders community in an island state, Chloe, a member of the communications team, sat down with Kyra Calbero, Interim Executive Director of the foundation's…
Abríl es el mes nacional de la salud de las minorías. Para aprender sobre las experiencias de la comunidad de trastornos hemorrágicas en un lugar hispanohablante, Chloe, un miembro del equipo de comunicación, habló con Anthony Llanes Rodríguez, el…
The U.S. Food and Drug Administration (FDA) has approved ALTUVIIIO ™, formerly known as efanesoctocog alfa, for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative management (surgery) for adults and…
During legislative session, NHF's chapter network, public policy staff, and the bleeding disorders community at large has been hard at work advocating across the United States! For the month of February, here are some advocacy and policy highlights…
uniQure recently announced publication of the clinical trial results associated with approval of the hemophilia gene therapy product Hemgenix®. The data, which were published in the New England Journal of Medicine, (NEJM), were drawn from the HOPE-B…